Characteristic Bands Manifesting as Zebra Lines on Radiographs in Osteogenesis Imperfecta

Ishizuka, Mariko; Tsuji, Shoji; Hirabayashi, Masato; Kaneko, Kazunari

doi:10.1007/s12098-017-2316-2

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yet when administered together with SclAb, both drugs combined led to cumulative gains on bone mass. At the site of concurrent treatment, PAM induced a sclerotic metaphyseal band consistent with previous observations of BP treatment stabilizing primary spongiosa near the growth plate . Treatment with PAM alone showed a significant effect on bone volume fraction for both Brtl/+ and WT when compared to untreated controls, solely due to a significant dose‐dependent preservation of Tb.N with no concurrent effect on Tb.Th.…”

Section: Discussionmentioning

confidence: 99%

Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model

Olvera

Stolzenfeld

Marini

et al. 2018

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

Osteogenesis imperfecta (OI) is a genetic disorder characterized by altered bone quality and imbalanced bone remodeling, leading to skeletal fractures that are most prominent during childhood. Treatments for OI have focused on restoring pediatric bone density and architecture to recover functional strength and consequently reduce fragility. Though antiresorptive agents like bisphosphonates (BPs) are currently the most common intervention for the treatment of OI, a number of studies have shown efficacy of sclerostin antibody (SclAb) in inducing gains in bone mass and reducing fragility in OI mouse models. In this study, the effects of the concurrent use of BP and SclAb were evaluated during bone growth in a mouse harboring an OI-causing Gly→Cys mutation on col1a1. A single dose of antiresorptive BP facilitated the anabolic action of SclAb by increasing availability of surfaces for new bone formation via retention of primary trabeculae that would otherwise be remodeled. Chronic effects of concurrent administration of BP and SclAb revealed that accumulating cycles conferred synergistic gains in trabecular mass and vertebral stiffness, suggesting a distinct advantage of both therapies combined. Cortical gains in mass and strength occurred through SclAb alone, independent of presence of BP. In conclusion, these preclinical results support the scientific hypothesis that minimal antiresorptive treatment can amplify the effects of SclAb during early stages of skeletal growth to further improve bone structure and rigidity, a beneficial outcome for children with OI. © 2018 American Society for Bone and Mineral Research.

show abstract

Section: Discussionmentioning

confidence: 99%